' 
![]()
SCIENTIFIC SCORE
Possibly Effective
Based on 48 Researches
7.5
USERS' SCORE
Good
Based on 1 Review
8.6
Supplement Facts
Serving Size: 2 Soft Gels
Amount Per Serving
%DV
Calories
20
Total Fat
2 g
3%
Saturated Fat
0 g
0%
Trans Fat
0 g
†
Vitamin D3 (cholecalciferol)
25 mcg (1000 IU)
125%
Total Omega-3s♦
1280 mg
†
EPA (Eicosapentaenoic Acid)
650 mg
†
DHA (Docosahexaenoic Acid)
450 mg
†
Top Medical Research Studies
9
Vitamin D3 reduces breast cancer invasion
Mitigation of Breast Cancer Cells' Invasiveness via Down Regulation of ETV7, Hippo, and PI3K/mTOR Pathways by Vitamin D3 Gold-Nanoparticles.
Direct evidence of effectiveness
We set out to explore how Vitamin D3, when combined with gold nanoparticles (VD3-GNPs), could influence breast cancer's aggressiveness. Our research focused on breast cancer cell lines, specifically MCF-7 and MDA-MB-231, to see if this innovative treatment could significantly reduce cancer cell migration and invasion.
Through a series of methods including Western blots and migration/invasion assays, we observed that the VD3-GNP treatment led to an impressive reduction in cancer aggressiveness, with migration and invasion rates dropping by over 45%. This effect seems to come from the downregulation of key pathways associated with cancer growth and spread, namely the PI3K/AKT/mTOR pathway, as well as ETV7 and the Hippo pathway.
What's particularly surprising is the fact that we achieved these results using a relatively low dose of Vitamin D3—three orders of magnitude lower than doses used in past studies. This makes VD3-GNPs an appealing option for non-toxic and cost-effective treatments aimed at combating breast cancer's aggressive nature.
Through a series of methods including Western blots and migration/invasion assays, we observed that the VD3-GNP treatment led to an impressive reduction in cancer aggressiveness, with migration and invasion rates dropping by over 45%. This effect seems to come from the downregulation of key pathways associated with cancer growth and spread, namely the PI3K/AKT/mTOR pathway, as well as ETV7 and the Hippo pathway.
What's particularly surprising is the fact that we achieved these results using a relatively low dose of Vitamin D3—three orders of magnitude lower than doses used in past studies. This makes VD3-GNPs an appealing option for non-toxic and cost-effective treatments aimed at combating breast cancer's aggressive nature.
Read More
9
Vitamin D3 inhibits breast cancer growth
Vitamin D3 Inhibits the Viability of Breast Cancer Cells In Vitro and Ehrlich Ascites Carcinomas in Mice by Promoting Apoptosis and Cell Cycle Arrest and by Impeding Tumor Angiogenesis.
Strong relevance to breast cancer
We explored the role of vitamin D3, or cholecalciferol, in combating breast cancer through a comprehensive study involving breast cancer cell lines and a mouse model called Ehrlich ascites carcinoma (EAC). To understand how vitamin D3 might affect cancer, we monitored its effects on both estrogen receptor-positive and negative cell lines in vitro, noting that these cells absorbed around 50% of vitamin D3 during a 48-hour incubation period.
Our results showcased that vitamin D3 significantly slowed down the proliferation of breast cancer cells in a dose-dependent manner, with effective inhibitory concentrations ranging from 0.10 to 0.35 mM. Prolonged exposure didn’t seem to boost its effectiveness, suggesting an optimal treatment window. Notably, vitamin D3 prompted cell cycle arrest and apoptosis—two crucial mechanisms for controlling cancer growth—through the regulation of specific proteins like p53, cyclin-D1, and Bcl2.
Furthermore, vitamin D3 demonstrated its potential as an anti-angiogenic agent by impeding blood vessel growth both in vitro and during experiments with chorioallantoic membranes. In our in vivo approach, administering vitamin D3 intraperitoneally in mice led to reduced tumor growth and body weight gain.
Overall, the findings indicate that vitamin D3 can exert cytotoxic effects on breast cancer cells and may serve as a valuable player in cancer therapy strategies. This prompts further investigation into its therapeutic applications against breast cancer.
Our results showcased that vitamin D3 significantly slowed down the proliferation of breast cancer cells in a dose-dependent manner, with effective inhibitory concentrations ranging from 0.10 to 0.35 mM. Prolonged exposure didn’t seem to boost its effectiveness, suggesting an optimal treatment window. Notably, vitamin D3 prompted cell cycle arrest and apoptosis—two crucial mechanisms for controlling cancer growth—through the regulation of specific proteins like p53, cyclin-D1, and Bcl2.
Furthermore, vitamin D3 demonstrated its potential as an anti-angiogenic agent by impeding blood vessel growth both in vitro and during experiments with chorioallantoic membranes. In our in vivo approach, administering vitamin D3 intraperitoneally in mice led to reduced tumor growth and body weight gain.
Overall, the findings indicate that vitamin D3 can exert cytotoxic effects on breast cancer cells and may serve as a valuable player in cancer therapy strategies. This prompts further investigation into its therapeutic applications against breast cancer.
Read More
9
DHA impacts breast cancer immunity
Docosahexaenoic acid (DHA) impairs hypoxia-induced cellular and exosomal overexpression of immune-checkpoints and immunomodulatory molecules in different subtypes of breast cancer cells.
Directly relevant DHA effects
We explored the role of docosahexaenoic acid (DHA), an omega-3 fatty acid, in altering the behavior of breast cancer cells, specifically focusing on how it impacts immune responses. Cancer cells often use immune-checkpoint molecules to evade our body’s natural defenses, and this study looked at whether DHA could influence the expression of these critical molecules.
By treating two types of breast cancer cells—MDA-MB-231 (triple negative) and BT-474 (triple positive)—with DHA under both normoxic and hypoxic (low oxygen) conditions for 24 hours, we observed notable changes. The study showed that hypoxia caused a significant increase in immune-checkpoints and immunomodulatory molecules. However, when we introduced DHA, the results were promising: there was a marked decrease in the expression of those immune markers.
Additionally, the treatment with DHA also led to an increase in regulatory microRNAs, which are important for controlling the immune response. These results suggest that DHA might play a supportive role in breast cancer therapy by reducing the mechanisms that allow cancer cells to escape immune surveillance. This could open pathways for new treatment options that integrate nutritional interventions like DHA supplementation alongside traditional cancer therapies.
By treating two types of breast cancer cells—MDA-MB-231 (triple negative) and BT-474 (triple positive)—with DHA under both normoxic and hypoxic (low oxygen) conditions for 24 hours, we observed notable changes. The study showed that hypoxia caused a significant increase in immune-checkpoints and immunomodulatory molecules. However, when we introduced DHA, the results were promising: there was a marked decrease in the expression of those immune markers.
Additionally, the treatment with DHA also led to an increase in regulatory microRNAs, which are important for controlling the immune response. These results suggest that DHA might play a supportive role in breast cancer therapy by reducing the mechanisms that allow cancer cells to escape immune surveillance. This could open pathways for new treatment options that integrate nutritional interventions like DHA supplementation alongside traditional cancer therapies.
Read More
Most Useful Reviews
9.5
No recurrence
I've been using this for over ten years. My wellness physician suggested these pills for my health, especially Vitamin D supplements, which I believe every woman should include. After two rounds of breast cancer, I have had no recurrence while taking these pills.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 48 Researches
7.5
9.5
Effective DHA and DTX combination
Improved Antitumor Efficacy of a Dextran-based Docetaxel-coupled Conjugate against Triple-Negative Breast Cancer.
Relevant to DHA's cancer effects
We explored the effectiveness of a new treatment strategy for breast cancer that combines docosahexaenoic acid (DHA) with docetaxel (DTX). In our study, we developed a dextran-based dual-drug conjugate that allows these two compounds to work together more effectively against breast cancer cells.
The conjugate we created showed promise in our tests, especially against triple-negative breast cancer, which is often more challenging to treat. We discovered that this new formulation not only improved the water solubility of DTX but also enabled it to reach the tumor more effectively, minimizing distribution to normal tissues.
Results demonstrated that this combination significantly inhibited tumor growth compared to traditional DTX treatments, nearly eliminating tumors in our mouse model without causing adverse systemic effects. This work suggests that when DHA is coupled with DTX, it enhances the potential for improved breast cancer treatments.
The conjugate we created showed promise in our tests, especially against triple-negative breast cancer, which is often more challenging to treat. We discovered that this new formulation not only improved the water solubility of DTX but also enabled it to reach the tumor more effectively, minimizing distribution to normal tissues.
Results demonstrated that this combination significantly inhibited tumor growth compared to traditional DTX treatments, nearly eliminating tumors in our mouse model without causing adverse systemic effects. This work suggests that when DHA is coupled with DTX, it enhances the potential for improved breast cancer treatments.
Read More
9
Vitamin D3 reduces breast cancer invasion
Mitigation of Breast Cancer Cells' Invasiveness via Down Regulation of ETV7, Hippo, and PI3K/mTOR Pathways by Vitamin D3 Gold-Nanoparticles.
Direct evidence of effectiveness
We set out to explore how Vitamin D3, when combined with gold nanoparticles (VD3-GNPs), could influence breast cancer's aggressiveness. Our research focused on breast cancer cell lines, specifically MCF-7 and MDA-MB-231, to see if this innovative treatment could significantly reduce cancer cell migration and invasion.
Through a series of methods including Western blots and migration/invasion assays, we observed that the VD3-GNP treatment led to an impressive reduction in cancer aggressiveness, with migration and invasion rates dropping by over 45%. This effect seems to come from the downregulation of key pathways associated with cancer growth and spread, namely the PI3K/AKT/mTOR pathway, as well as ETV7 and the Hippo pathway.
What's particularly surprising is the fact that we achieved these results using a relatively low dose of Vitamin D3—three orders of magnitude lower than doses used in past studies. This makes VD3-GNPs an appealing option for non-toxic and cost-effective treatments aimed at combating breast cancer's aggressive nature.
Through a series of methods including Western blots and migration/invasion assays, we observed that the VD3-GNP treatment led to an impressive reduction in cancer aggressiveness, with migration and invasion rates dropping by over 45%. This effect seems to come from the downregulation of key pathways associated with cancer growth and spread, namely the PI3K/AKT/mTOR pathway, as well as ETV7 and the Hippo pathway.
What's particularly surprising is the fact that we achieved these results using a relatively low dose of Vitamin D3—three orders of magnitude lower than doses used in past studies. This makes VD3-GNPs an appealing option for non-toxic and cost-effective treatments aimed at combating breast cancer's aggressive nature.
Read More
9
Vitamin D3 enhances breast cancer treatment
Coadministration of doxorubicin with vitamin D3, Lactobacillus acidophilus, and Lactobacillus casei in the 4T1 mouse model of breast cancer: anticancer and enteroprotective effects.
Combination treatment limits isolation
We aimed to understand how vitamin D3 influences breast cancer treatment by testing it alongside doxorubicin (Dox) and probiotics using a group of mice. The study involved female BALB/c mice that were divided into various groups to see how these treatments affected tumor growth and overall health compared to a control group.
Our findings showed that the combinations of Dox with vitamin D3 and probiotics significantly reduced tumor size and weight, indicating that vitamin D3 may enhance the effectiveness of breast cancer chemotherapy. The study also found that these combinations had protective effects against the toxicity typically caused by Dox. Especially notable was the increase in genes associated with tumor reduction and a decrease in those linked to cancer cell survival.
However, it’s essential to note that this study focused on the combined effects of vitamin D3, probiotics, and Dox, which makes it challenging to isolate the specific impact of vitamin D3 alone on breast cancer outcomes. Overall, the results suggest that incorporating vitamin D3 into breast cancer treatment protocols could be beneficial, particularly in combination with other agents.
Our findings showed that the combinations of Dox with vitamin D3 and probiotics significantly reduced tumor size and weight, indicating that vitamin D3 may enhance the effectiveness of breast cancer chemotherapy. The study also found that these combinations had protective effects against the toxicity typically caused by Dox. Especially notable was the increase in genes associated with tumor reduction and a decrease in those linked to cancer cell survival.
However, it’s essential to note that this study focused on the combined effects of vitamin D3, probiotics, and Dox, which makes it challenging to isolate the specific impact of vitamin D3 alone on breast cancer outcomes. Overall, the results suggest that incorporating vitamin D3 into breast cancer treatment protocols could be beneficial, particularly in combination with other agents.
Read More
9
EB1089 enhances HER2-positive treatments
EB1089 Increases the Antiproliferative Response of Lapatinib in Combination with Antiestrogens in HER2-Positive Breast Cancer Cells.
Moderate relevance to breast cancer
We aimed to understand how EB1089, a vitamin D3 analog, influences the treatment of HER2-positive breast cancer when combined with established therapies like lapatinib and antiestrogens. In our research, we used two types of breast cancer cells—BT-474 and SK-BR-3—both of which are HER2-positive but have differing estrogen receptor statuses.
Our findings revealed that EB1089 significantly boosted the antiproliferative effects of lapatinib when used together with antiestrogens. Notably, in the SK-BR-3 cells, which are estrogen receptor-negative, EB1089 successfully restored the effectiveness of antiestrogen treatment. This shows that EB1089 plays a pivotal role in enhancing cell growth inhibition in HER2-positive breast cancer cells.
Additionally, we discovered that this analog modulated the expression of the estrogen receptor alpha protein and reduced Akt phosphorylation, contributing to its effects. Overall, our investigation highlights the potential of incorporating vitamin D3 analogs like EB1089 into existing cancer treatment regimens, opening new avenues for managing HER2-positive breast cancer more effectively.
Our findings revealed that EB1089 significantly boosted the antiproliferative effects of lapatinib when used together with antiestrogens. Notably, in the SK-BR-3 cells, which are estrogen receptor-negative, EB1089 successfully restored the effectiveness of antiestrogen treatment. This shows that EB1089 plays a pivotal role in enhancing cell growth inhibition in HER2-positive breast cancer cells.
Additionally, we discovered that this analog modulated the expression of the estrogen receptor alpha protein and reduced Akt phosphorylation, contributing to its effects. Overall, our investigation highlights the potential of incorporating vitamin D3 analogs like EB1089 into existing cancer treatment regimens, opening new avenues for managing HER2-positive breast cancer more effectively.
Read More
9
Combination therapy shows promise
Anticancer and anti-metastasis activity of 1,25 dihydroxycholecalciferols and genistein in MCF-7 and MDA-MB-231 breast cancer cell lines.
Key findings on vitamin D3
We investigated the potential impact of 1,25 dihydroxycholecalciferols, commonly known as vitamin D3, alongside genistein, a dietary phytoestrogen, on breast cancer cell lines, specifically MCF-7 and MDA-MB-231. Our research focused on their ability to inhibit cancer cell growth, progression, and metastasis, both individually and in combination.
Through a series of assays, including flow cytometry and cell invasion tests, we observed that vitamin D3 and genistein were effective in reducing cell proliferation. Notably, they prompted the cancer cells to enter a resting phase and triggered the process of apoptosis, or programmed cell death. We found that this was linked to increased expression of certain genes like BAX and CASP3 and decreased levels of the BCL-2 gene, a key player in cell survival.
Interestingly, both compounds also showed promise in curbing metastasis. They enhanced the expression of E-cadherin, a protein that helps cells stick together, while reducing the expression of other proteins associated with cancer spread. Furthermore, these treatments also positively influenced key protein expressions that enhance cancer response and overall survivability.
Ultimately, our findings suggest that vitamin D3, especially in combination with genistein, holds potential as a candidate for breast cancer treatment. However, given the combined approach, isolating the effects of vitamin D3 alone remains challenging, which adds complexity to our understanding.
Through a series of assays, including flow cytometry and cell invasion tests, we observed that vitamin D3 and genistein were effective in reducing cell proliferation. Notably, they prompted the cancer cells to enter a resting phase and triggered the process of apoptosis, or programmed cell death. We found that this was linked to increased expression of certain genes like BAX and CASP3 and decreased levels of the BCL-2 gene, a key player in cell survival.
Interestingly, both compounds also showed promise in curbing metastasis. They enhanced the expression of E-cadherin, a protein that helps cells stick together, while reducing the expression of other proteins associated with cancer spread. Furthermore, these treatments also positively influenced key protein expressions that enhance cancer response and overall survivability.
Ultimately, our findings suggest that vitamin D3, especially in combination with genistein, holds potential as a candidate for breast cancer treatment. However, given the combined approach, isolating the effects of vitamin D3 alone remains challenging, which adds complexity to our understanding.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.6
9.5
No recurrence
I've been using this for over ten years. My wellness physician suggested these pills for my health, especially Vitamin D supplements, which I believe every woman should include. After two rounds of breast cancer, I have had no recurrence while taking these pills.
